Common use of Informal Discussions Clause in Contracts

Informal Discussions. Except as otherwise provided herein, in the event of any controversy or claim arising out of or relating to this Agreement, or the rights or obligations of the Parties hereunder, or the relationship between the Parties with respect to Licensed Compound or Licensed Product, the Parties shall first try to settle their differences amicably between themselves. Any Party may initiate such informal dispute resolution by sending written notice of the dispute to the other Parties, and within thirty (30) days after such notice appropriate representatives of the Parties shall meet for attempted resolution by good faith negotiations. If such representatives are unable to resolve such disputed matter within thirty (30) days, any Party may refer the matter by written notice to the others to the Worldwide Head of Licensing, Merck Research Laboratories, or his designee, and the Chief Executive Officer of Tigercat, or his designee, for discussion and resolution. If such individuals or their designees are unable to resolve such dispute within thirty (30) days of such written notice or if the recipient Party does not respond within thirty (30) days of such written notice, any Party may initiate arbitration proceedings in accordance with the provisions of this Article XIII.

Informal Discussions. Except as otherwise provided herein, in the event of any controversy or claim arising out of or relating to this Agreement, or the rights or obligations of the Parties hereunder, or the relationship between the Parties with respect to the Licensed Compound Compounds or Licensed Product, the Parties shall first try to settle their differences amicably between themselves. Any Either Party may initiate such informal dispute resolution by sending written notice of the dispute to the other PartiesParty, and within thirty (30) days after such notice appropriate representatives of the Parties shall meet for attempted resolution by good faith negotiations. If such representatives are unable to resolve promptly such disputed matter within the said thirty (30) days, any either Party may refer the matter by written notice to the others other to the Worldwide Head appropriate therapy area Vice President of Licensing, Merck Research Laboratories, or his designee, and the Chief Executive Officer of TigercatLicensee, or his designee, for discussion and resolution. If such individuals or their designees are unable to resolve such dispute within thirty (30) days of such written notice or if the recipient Party does not respond within thirty (30) days of such written notice, any either Party may initiate arbitration proceedings in accordance with the provisions of this Article XIII.

Informal Discussions. Except as otherwise provided herein, in the event of any controversy or claim arising out of or relating to this Agreement, or the rights or obligations of the Parties hereunder, or the relationship between the Parties with respect to the Licensed Compound or Licensed Product, the Parties shall first try to settle their differences amicably between themselves. Any Either Party may initiate such informal dispute resolution by sending written notice of the dispute to the other PartiesParty, and within thirty (30) days after such notice appropriate representatives of the Parties shall meet for attempted resolution by good faith negotiations. If such representatives are unable to resolve promptly such disputed matter within the said thirty (30) days, any either Party may refer the matter by written notice to the others other under Section 14.07 to the Worldwide Head Vice President of Licensing, Merck Research LaboratoriesLilly, or his designee, and the Chief Executive Officer of TigercatLicensee, or his designee, for discussion and resolution. If such individuals or their designees are unable to resolve such dispute within thirty sixty (30) days of such written notice or if the recipient Party does not respond within thirty (3060) days of such written notice, any either Party may initiate arbitration proceedings in accordance with the provisions of this Article XIII.

Informal Discussions. Except as otherwise provided herein, in the event of any controversy or claim arising out of or relating to this Agreement, or the rights or obligations of the Parties hereunder, or the relationship between the Parties with respect to Licensed Compound or Licensed Product, the Parties shall first try to settle their differences amicably between themselves. Any Either Party may initiate such informal dispute resolution by sending written notice of the dispute to the other PartiesParty, and within thirty (30) days after such notice appropriate representatives of the Parties shall meet for attempted resolution by good faith negotiations. If such representatives are unable to resolve promptly such disputed matter within the said thirty (30) days, any either Party may refer the matter by written notice to the others other to the Worldwide Head appropriate therapy area Vice President of Licensing, Merck Research Laboratories, or his designee, and the Chief Executive Officer of TigercatLicensee, or his designee, for discussion and resolution. If such individuals or their designees are unable to resolve such dispute within thirty (30) days of such written notice or if the recipient Party does not respond within thirty (30) days of such written notice, any either Party may initiate arbitration proceedings in accordance with the provisions of this Article XIII.

Informal Discussions. Except as otherwise provided herein, in the event of any controversy or claim arising out of or relating to this AgreementMSA, or the rights or obligations of the Parties hereunder, or the relationship between the Parties with respect to Licensed Compound or Licensed Product, the Parties shall first try to settle their differences amicably between themselvesthemselves through the Core Team and then JSC level. Any Thereafter, either Party may initiate such informal dispute resolution on the Executive level by sending written notice of the dispute to the other PartiesParty, and within thirty fifteen (3015) days after such notice appropriate representatives Executives of the Parties shall meet for attempted attempt resolution by good faith negotiations. If such representatives are unable to resolve promptly such disputed matter within thirty the said fifteen (3015) days, any either Party may refer the matter by written notice to the others to Chief Executive Officer of the Worldwide Head of Licensing, Merck Research Laboratoriesother Party, or his his/her designee, and the Chief Executive Officer of Tigercat, or his designeesuch Party, for discussion and resolution. If such individuals or their designees are unable to resolve such dispute within thirty (30) days of such written notice or if the recipient Party does not respond within thirty (30) days of such written notice, any either Party may initiate arbitration proceedings in accordance with the provisions of this Article XIII15.

Informal Discussions. Except as otherwise provided herein, in the event of any controversy or claim arising out of or relating to this AgreementMSA, or the rights or obligations of the Parties hereunder, or the relationship between the Parties with respect to Licensed Compound or Licensed Product, the Parties shall first try to settle their differences amicably between themselvesthemselves through the Core Team and then JSC level. Any Thereafter, either Party may initiate such informal dispute resolution on the executive level by sending written notice of the dispute to the other PartiesParty, and within thirty (30) days after such notice appropriate representatives executives of the Parties shall meet for attempted resolution by good faith negotiations. If such representatives are unable to resolve promptly such disputed matter within the said thirty (30) days, any either Party may refer the matter by written notice to the others to Chief Executive Officer of the Worldwide Head of Licensing, Merck Research Laboratoriesother Party, or his his/her designee, and the Chief Executive Officer of Tigercat, or his designeesuch Party, for discussion and resolution. If such individuals or their designees are unable to resolve such dispute within thirty (30) days of such written notice or if the recipient Party does not respond within thirty (30) days of such written notice, any either Party may initiate arbitration proceedings in accordance with the provisions of this Article XIII16.

Informal Discussions. Except as otherwise provided herein, in In the event of any controversy or claim arising out of or relating to this Agreement, or the rights or obligations of the Parties hereunder, or the relationship between the Parties with respect to the Licensed Compound Compounds, Licensed Products, Patent Rights, Licensor Know-How or Licensed ProductTrademarks in the Field, the Parties shall first try to settle their differences amicably between themselves. Any Either Party may initiate such informal dispute resolution by sending written notice of the dispute to the other PartiesParty, and within thirty (30) 30 days after such notice appropriate representatives of the Parties shall meet for attempted resolution by good faith negotiations. If such representatives are unable to resolve promptly such disputed matter within thirty (30) the said 30 days, any either Party may refer the matter by written notice to the others other to the Worldwide Head Chief Executive Officer of Licensing, Merck Research LaboratoriesLicensor, or his her designee, and the Chief Executive Officer of TigercatLicensee, or his designee, for discussion and resolution. If such individuals or their designees are unable to resolve such dispute within thirty (30) days of such written notice or if the recipient Party does not respond within thirty (30) 30 days of such written notice, any either Party may initiate arbitration proceedings in accordance with the provisions of this Article XIII12.

Informal Discussions. Except as otherwise provided herein, in the event of any controversy or claim arising out of or relating to this AgreementMSA, or the rights or obligations of the Parties hereunder, or the relationship between the Parties with respect to Licensed Compound or Licensed Product, the Parties shall first try to settle their differences amicably between themselvesthemselves through the Core Team and then JSC level. Any Thereafter, either Party may initiate such informal dispute resolution on the Executive level by sending written notice of the dispute to the other PartiesParty, and within thirty (30) days after such notice appropriate representatives Executives of the Parties shall meet for attempted resolution by good faith negotiations. If such representatives are unable to resolve promptly such disputed matter within the said thirty (30) days, any either Party may refer the matter by written notice to the others to Chief Executive Officer of the Worldwide Head of Licensing, Merck Research Laboratoriesother Party, or his his/her designee, and the Chief Executive Officer of Tigercat, or his designeesuch Party, for discussion and resolution. If such individuals or their designees are unable to resolve such dispute within thirty (30) days of such written notice or if the recipient Party does not respond within thirty (30) days of such written notice, any either Party may initiate arbitration proceedings in accordance with the provisions of this Article XIII16.

Informal Discussions. Except as otherwise provided herein, in the event of any controversy or claim arising out of or relating to this Agreement, or the rights or obligations of the Parties hereunder, or the relationship between the Parties with respect to the Licensed Compound Compounds or Licensed ProductProducts, the Parties shall first try to settle their differences amicably between themselves. Any Either Party may initiate such informal dispute resolution by sending written notice of the dispute to the other PartiesParty, and within thirty (30) days after such notice appropriate representatives of the Parties shall meet for attempted resolution by good faith negotiations. If such representatives are unable to resolve promptly such disputed matter within the said thirty (30) days, any either Party may refer the matter by written notice to the others to the Worldwide Head of Licensing, Merck Research Laboratories, or his designee, and the Chief Executive Officer of Tigercat, or his designee, Officers for discussion and resolution. If such individuals or their designees Executive Officers are unable to resolve such dispute within thirty (30) days of such written notice or if the recipient Party does not respond within thirty (30) days of such written notice, any either Party may initiate arbitration proceedings in accordance with the provisions of this Article XIIISection 10.4.